Evaluation of Stearylamine-Modified Liposomes for the Oral Vaccine Adjuvant | OMICS International | Abstract
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Evaluation of Stearylamine-Modified Liposomes for the Oral Vaccine Adjuvant

Division of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Izumisano, Japan
Corresponding Author : Watarai S
Division of Veterinary Science
Graduate School of Life and Environmental Sciences
Osaka Prefecture University, 1-58 Rinkuohraikita
Izumisano, Osaka 598-8531, Japan
Tel: +81-72-463-5720
Fax: +81-72-463-5720
E-mail: [email protected]
Received March 25, 2014; Accepted April 27, 2014; Published May 02, 2014
Citation: Watarai S and Sasaki Y (2014) Evaluation of Stearylamine-Modified Liposomes for the Oral Vaccine Adjuvant. J Infect Dis Ther 2:141. doi:10.4172/2332-0877.1000141
Copyright: © 2014 Watarai S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google


The usefulness of stearylamine (SA)-modified liposomes for the oral vaccine adjuvant in the induction of immune responses was evaluated. Mice were orally immunized withunmodified liposomes containing ovalbumin (OVA) (group I), OVA-containing monophosphoryl lipid A (MPL)-modified liposomes (group II), OVA-having SA-modified liposomes (group III) or OVA alone (group IV). After immunization, significant OVA-specific antibodies were detected in the serum and intestine from mice of groups I to III, but not in group IV. Especially, intestinal IgG and IgA antibody responses against OVA were significantly higher in mice of group III than in groups I and II. When sera were analyzed for isotype distribution,OVA-specific IgG1 antibody responses were noted in mice of groups I and II, whereas the induction of OVA-specific IgG1 and IgG3 antibody responses was observed in mice of group III. Moreover, substantial production of IFN-γ(Th1-type) and IL-4 (Th2 type) was demonstrated in spleen cells from mice of group III in vitro. These results suggest that the SA-modified liposomes would serve effectively as mucosal vaccine adjuvant for inducing humoral and cell-mediated immune responses.